Litcius/Paper detail

Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up

Han Zhang, Wei Zhao, Xiaoyan Zhang, Lei Zhang, Run Guo, Han Huang, Li Lin, Feng Liu, Haidan Chen, Fangfang Shen, Jinzhun Wu, Xiaowen Huang, Xiaoping Zhu, Feng Li, Gang Zou, Jason Chien, Michael Humphries, Quan Lü, Jim Zhen Wu, Shunying Zhao, Hanmin Liu, Xin Ni, Hanmin Liu, Xin Ni, Cilang Hu, Xueyun Lv, Lili Chen, Shanshan Deng, Kun Jiang, Zhengxiu Luo, Weiling Qiu, Wenhui Jiang, Hongmei Qiao, Yanli Zhang, Jing Liu, Ling Liu, Yanmin Bao, Yiping Chen, Yue Li, Zhaobo Shen, Linan Chen, Hebin Chen, Chuangli Hao

2025The Lancet Child & Adolescent Health13 citationsDOI

Topics & Concepts

MedicinePediatricsRespiratory systemRespiratory tract infectionsInternal medicineRespiratory viral infections researchVirus-based gene therapy researchSARS-CoV-2 detection and testing
Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up | Litcius